0CUM.L
Orphazyme A/S [0CUM.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
0CUM.L Stock Summary
In the News
0CUM.L Financial details
Company Rating
-
Market Cap
34.82K
Income
-37.23K
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1
Optionable
No
Shortable
Yes
Earnings
-
P/E
-2.72
Forward P/E
-
PEG
0.51
P/S
-
P/B
1.2
P/C
-
P/FCF
-2.87
Quick Ratio
4.16
Current Ratio
4.96
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.06
EPS next Y
-
EPS next Q
-
EPS this Y
-51.56%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-35%
ROE
-36%
ROC
-0.44%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0-1.252
52W High
-
52W Low
-
RSI
-
Rel Volume
16.52
Avg Volume
85
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.143
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
Company Profile
- Volume Average 85
- Market Capitalization 34.82K
- Employee 1
- CEO Mr. Jakob Færch Bendtsen
- Headquarters Copenhagen,DK
- IPO Date 2018-02-12
-
Website
https://www.orphazyme.com 
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative rare diseases. The company offers heat stock proteins that focuses on the treatment of neurodegenerative diseases by harnessing the cell protective properties of the heat shock response, which protects cells from the accumulation of misfolded proteins, aggregated proteins, and dysfunctional lysosomes. Its lead candidate is the Arimoclomol, which is in clinical development for diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, and Inclusion Body Myositis. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
